{"name":"Amgen Research (Munich) GmbH","slug":"amgen-research-munich-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AMG 223","genericName":"AMG 223","slug":"amg-223","indication":"Hypercholesterolemia","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Adecatumumab and FOLFOX","genericName":"Adecatumumab and FOLFOX","slug":"adecatumumab-and-folfox","indication":"Colorectal cancer","status":"phase_2"}]}],"pipeline":[{"name":"AMG 223","genericName":"AMG 223","slug":"amg-223","phase":"phase_2","mechanism":"AMG 223 is a human monoclonal antibody that targets PCSK9.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"Adecatumumab and FOLFOX","genericName":"Adecatumumab and FOLFOX","slug":"adecatumumab-and-folfox","phase":"phase_2","mechanism":"Adecatumumab is a monoclonal antibody targeting EpCAM, while FOLFOX is a chemotherapy regimen combining oxaliplatin, 5-fluorouracil, and leucovorin.","indications":["Colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBVd0FTbFNfYWd5Qll0YTVSUnZGREx1dWtOV2FSSGgyOFpiSWZJTFR0ZERnSWlveU0xWDBSY0hjNHA2RDhoc2lWSmpMVUlDQjFmZG5aMGFpd1lyNDJnUkVJ?oc=5","date":"2025-11-13","type":"trial","source":"nature.com","summary":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study - nature.co","headline":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQVnpIbWMxdzdpeE0tT1BvaUp5b3F0ZHM1VjNZcXNhSExVandfaG53TU5Ld2hOdVhPTTVSWHlPT1ppYWNORVJCQ3RudFlaZFhaNUgybzluTlFNaC1ITGFuTjhuRHg4bVRyR2cwaFViX0wyVHhfc09sM2NES1NQbUpYMGphR3dubGtW?oc=5","date":"2025-04-21","type":"earnings","source":"Fierce Pharma","summary":"The top 20 pharma companies by 2024 revenue - Fierce Pharma","headline":"The top 20 pharma companies by 2024 revenue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFAwS3ZaTTlGOHU3Y0pyVjBtN3l0ekhHWnRveGtPNlgxemVVcWwxZ0dhUFcwZ1hVeFktdmR4Z3owVHZhSU9BZzdDYzBnMVgwdmdVN0tKZjdFZUVUMTJyZzVv?oc=5","date":"2024-08-22","type":"pipeline","source":"nature.com","summary":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse | Leukemia - nat","headline":"Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE84bmdQSkNCUFJCSm50RDhJX0pvTGRDLUpkY0U4TEx1cWtnNzJZOVZIT2lhb2NvT0tyRzZjZC1pWlcwMlRVeGZBaUxYU3ROMkZsNDI0a1JCVTZBY29FU2Fz?oc=5","date":"2024-03-14","type":"pipeline","source":"nature.com","summary":"Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany - nature.com","headline":"Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4wVEdtQ25PSnRmZTBlWlRWNjh2R1lwSmc0cW85eWpndDk0bGdxbFBoemxGMThWdVM2UEdRSXBzSlg1WHR4UGFmVEVVX3J0UHpEdjQtVWtJV2pJM3E5clA0?oc=5","date":"2024-02-07","type":"regulatory","source":"nature.com","summary":"Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression | Bone Marrow Transplantation - nature.com","headline":"Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9BZURPUHhDX2YxWm43RnREZHdDMVpFUm5DNlRMSDZxS1Fzcm5FaFc4cElCSzZQNzlfSTF6X3JqOFNPZm94a2t0Ukg1TW5iTVJ0QU1oLVVyMW5YNWFMOWlZQ3I3NGNjOUl4?oc=5","date":"2024-02-05","type":"pipeline","source":"Wiley Online Library","summary":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia - Wiley Online Library","headline":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5pYW5uQjg4ZVpHbWVvd1ZUc0k3NTN5VEY5UDBWdDcyS2Zac0ktSUpoNmhuSDZUQzZGcGFKWXFRdWM2Mi1hMVYtajZ6THp5WjdkUVhLWi1YSlRHQlh1djI4?oc=5","date":"2023-01-04","type":"trial","source":"nature.com","summary":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study - nature.com","headline":"Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9qTUNLT1dnM1k5UkFFd1Y1YzNxVWxhNThDb2lqSGtuaDRZTXFYcndZMU1mLWVlVHVuemtlMlN5aGgyN2pjUl9jaGNCR3k0cVpuWlhBQmVNQ1BlTUZzai1j?oc=5","date":"2022-12-08","type":"pipeline","source":"nature.com","summary":"Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL - nature.com","headline":"Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE11WnFiUDFJMlVSdXc5YnRKYmRTZGxNM3NOR1RBc05kNm01ckZmaVpwcGpydWtha2x0WVNHbXFwdVpqQWhMM3I2b3RxSkp0RHQwVmZSTGZ2LUFzNWc3b0s2SmtoUFdQRm5xdXo4R2k5SDg4OFFh?oc=5","date":"2020-11-03","type":"pipeline","source":"Wiley","summary":"Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab - Wiley","headline":"Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9GSDc5OFVGVHlSYXlvVzZsbWZ5RTFZZy1IVHZLc3pRZVNTWlAteWJNbE9SMm5lMWxNakVOUUt6NWRBMi1oSS1ENHM0Mnc5S3hySEpHSG1hVlE5S0IwcDRQUnpBS3lCVjl4cWxQRTlPclZ6NTQy?oc=5","date":"2020-05-13","type":"pipeline","source":"Wiley","summary":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types - Wiley","headline":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy ac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE11eERnYWh0YjNDWkVmQWp0YVBhVHh3N1hJczlmSmllQ2NpTlU5amwtQ0plOWc3OVVFVFBGeTl1OHVUYUsxSW1WY1VHTWFsemU1Mk4zVEd4SHpVYU50ZWtZbklweWVZdFhIVnhVZDcwTmdZZVJ2N09qNDNR?oc=5","date":"2016-05-03","type":"trial","source":"Wiley","summary":"Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies - Wiley","headline":"Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}